Surrozen (NASDAQ:SRZN) & Spyre Therapeutics (NASDAQ:SYRE) Head to Head Analysis

Surrozen (NASDAQ:SRZN) and Spyre Therapeutics (NASDAQ:SYRE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Institutional & Insider Ownership

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Surrozen has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.99, suggesting that its share price is 199% more volatile than the S&P 500.

Profitability

This table compares Surrozen and Spyre Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
Spyre Therapeutics	N/A	-30.74%	-22.23%

Analyst Recommendations

This is a summary of current ratings and price targets for Surrozen and Spyre Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1	1	4	1	2.71
Spyre Therapeutics	1	1	12	1	2.87

Surrozen presently has a consensus price target of $45.00, indicating a potential upside of 171.90%. Spyre Therapeutics has a consensus price target of $109.69, indicating a potential upside of 21.54%. Given Surrozen’s higher possible upside, research analysts clearly believe Surrozen is more favorable than Spyre Therapeutics.

Earnings & Valuation

This table compares Surrozen and Spyre Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48 million	55.21	-$242.03 million	($40.55)	-0.41
Spyre Therapeutics	$890,000.00	8,917.51	-$155.20 million	($1.95)	-46.28

Spyre Therapeutics has lower revenue, but higher earnings than Surrozen. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Summary

Spyre Therapeutics beats Surrozen on 9 of the 14 factors compared between the two stocks.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

About Spyre Therapeutics

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.